ASX-listed fertility treatment group Monash IVF has appointed David Morris as new CEO:
ASX-listed fertility treatment group Monash IVF has announced David Morris as new chief executive officer and managing director from next month from 13th November.
Mr Morris joins the this famous fertility treatment group after 13 years at hearing implant company Cochlear Limited, where he was chief strategy officer at until mid-2016.
Previously Mr Morris worked at professional services group Accenture and has been a non-executive director of JewishCare NSW since 2015.
In a statement to the ASX on Wednesday, Monash IVF said its new CEO and MD would begin on November 13 with pay packet comprising a $500,000 base salary and up to $600,000 in long and short-term incentives.
Outgoing CEO James Thiedeman announced his resignation in May after eight years at the helm, saying he would be taking a role with an unlisted healthcare organisation.
News Resource – The Australian, October 18, 2017